

OFFICE OF THE SECRETARY OF STATE
DENNIS RICHARDSON
SECRETARY OF STATE

LESLIE CUMMINGS
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION
MARY BETH HERKERT
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

NOTICE OF PROPOSED RULEMAKING
INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 850
OREGON BOARD OF NATUROPATHIC MEDICINE

FILED
10/19/2018 12:13 PM
ARCHIVES DIVISION
SECRETARY OF STATE

FILING CAPTION: Clarifies Formulary Compendium Exclusions

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 11/26/2018 5:00 PM

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

A public rulemaking hearing may be requested in writing by 10 or more people, or by a group with 10 or more members, within 21 days following the publication of the Notice of Proposed Rulemaking in the Oregon Bulletin or 28 days from the date the Notice was sent to people on the agency mailing list, whichever is later. If sufficient hearing requests are received, the notice of the date and time of the rulemaking hearing must be published in the Oregon Bulletin at least 14 days before the hearing.

CONTACT: Mary-Beth Baptista 800 NE Oregon Street
971-673-0193, Ext. 0193 Suite 407
marybeth.baptista@state.or.us Portland, OR 97232

Filed By:
Mary-Beth Baptista
Rules Coordinator

NEED FOR THE RULE(S):

Clarifies substances excluded from the Formulary Compendium and corrects citation error.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

None

FISCAL AND ECONOMIC IMPACT:

None

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

none

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

none

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

The Oregon Board of Naturopathic Medicine consulted with the Board's Formulary Committee prior to amending the rule. The Formulary Committee's established purpose is to advise and establish the formulary of drugs that may be administered or prescribed by a naturopathic physician. The council is tasked with reviewing the formulary periodically.

If the council determines that the drug may be beneficial in the practice of naturopathic medicine it may add the drug to or amend the formulary.

RULES PROPOSED:

850-060-0223, 850-060-0226

AMEND: 850-060-0223

RULE SUMMARY: The rule excludes certain substances from the Formulary Compendium listed by classification in OAR 850-060-0226 for use by Naturopathic Physicians.

CHANGES TO RULE:

850-060-0223

Formulary Compendium Exclusions

The Formulary Council has approved substances as listed by classification in 850-060-0226 for use by Naturopathic physicians in accordance with professional standards of care. ¶

(1) This authority does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents or any other education and training required to prescribe, dispense, administer or order all legend or controlled substances. ¶

(2) Additionally, the following substances may not be prescribed by licensees of this Board ~~without approved specialized education and training.~~ ¶

(a) General anesthetics ¶

(b) Injectable Ketamine ¶

(c) Barbiturates; except with the exception of the following: ¶

(i) Phenobarbital: ¶

(ii) Butalbital ¶

(iii) Primidone ¶

(d) Systemic oncology agents with the exception of the following antineoplastic agents (oral and topical only) ¶

(A) 5FU; ¶

(B) Anastrozole; ¶

(C) Letrozole; ¶

(D) Mechlorethamine; ¶

(E) Megestrol; ¶

(F) Mercaptopurine; ¶

(G) Methotrexate; ¶

(H) Tamoxifen; ¶

(I) Tretinoin; ¶

(e) General anesthetics; ¶

(d) Oxytocics Mifepristone and mife Misopriostone used as an abortifacient; ¶

(e) Any other substance not listed in 850-060-0226 classification or meeting prior approval of the Board.

Statutory/Other Authority: ORS 685.125

Statutes/Other Implemented: ORS 685.030

AMEND: 850-060-0226

RULE SUMMARY: Incorporates the American Hospital Formulary Service Pharmacologic-Therapeutic Classification as the Formulary Compendium for Naturopathic Physicians with specific exclusions listed in 850-060-0223.

CHANGES TO RULE:

850-060-0226

Formulary Compendium Classifications

The Formulary Council has approved the current American Hospital Formulary Service Pharmacologic-Therapeutic Classification. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents or the exclusions listed in 850-060-0220.³ The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.

Statutory/Other Authority: ORS 685.125

Statutes/Other Implemented: ORS 685.145